HO 0303

Drug Profile

HO 0303

Alternative Names: HO-03-03; HO/03/03; Truheal

Latest Information Update: 17 Jun 2015

Price : $50

At a glance

  • Originator HealOr
  • Class Anti-inflammatories
  • Mechanism of Action Protein kinase C inhibitors; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic wounds; Diabetic foot ulcer

Most Recent Events

  • 17 Jun 2015 No recent reports on development identified - Phase-II/III for Diabetic foot ulcer in India and USA (Topical)
  • 17 Jun 2015 No recent reports on development identified - Phase-I for Chronic wounds in Israel (Topical)
  • 03 Apr 2013 HealOr completes enrolment in its phase II/III trial for Diabetic foot ulcer in USA & India (NCT00926068)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top